Resources
Nobody owns your AI agents.
Only 7.2 percent of organizations can name the human accountable when an agent acts.
AI governance failures are ownership failures. Only 7.2 percent of organizations have a named individual formally accountable for AI agent behavior, while half have already had a security incident tied to an unauthorized or misconfigured agent. This collection covers accountability models, audit trail design, EU AI Act obligations, and the governance structures that survive inspection.
That architecture is not exciting. It is ontology layers, governance scaffolding, MLR workflow design, audit trails, and human in the loop accountability. Boring infrastructure that does not photograph well in an annual report. Foundational work that makes the difference between an AI deployment that ships and one that quietly stalls in pilot for the third year running.
This collection covers AI governance as an ownership problem rather than a policy one. Who is accountable when an agent acts, what an audit trail has to capture to survive inspection, what the EU AI Act actually obliges you to do, and why one uniform AI policy is the thing most likely to break your deployment. Written for the people who will be asked to answer for it.
Key Insights
What the writing is showing.
Only 7.2 percent of organizations have a named individual with formal accountability for AI agent behavior.
Gartner projects 40 percent of enterprises will demote or decommission autonomous AI agents by 2027 due to governance gaps found only after production incidents.
EU AI Act penalties reach 35 million euros or 7 percent of global annual turnover for the most serious violations.
Read Deeper
Articles in this collection.
AI, Business
Only 7.2% of Companies Have a Named Owner for Their AI Agents
Only 7.2 percent of organizations have someone formally accountable for AI agent behavior. Half had an agent security incident in six months. Those are the same story.
Sep 14 · 3 min read
Pharma, AI
AI in Pharmacovigilance: The 18-Month Window
Pharmacovigilance is the function where the volume math has already broken. Manual processing cannot scale. AI is forced, not optional.
May 26 · 3 min read
Pharma, AI, Business
Pharma Boards Are Approving AI They Don't Understand
Pharma boards are signing off on billion-dollar AI commitments while two-thirds of directors admit they have limited or no AI knowledge.
May 25 · 3 min read
Pharma, Business, AI
What the EU AI Act Means for Pharma
Most of the AI a pharma company is currently building lands in the high-risk tier of the EU AI Act by default.
May 24 · 3 min read
Pharma, AI
The Audit Trail Problem: Why Pharma's AI Deployments Will Face FDA Scrutiny by 2027
The FDA issued 40 untitled letters in a single day in September 2025. The next enforcement wave will target AI-driven decisions without audit trails. Here is why your pharma company needs to act now.
May 11 · 3 min read
Pharma, AI
Why I Built Human in the Loop for Pharma
Pharma leaders make hundreds of decisions a week with no audit trail. Human in the Loop is the AI deployment model that makes pharma accountable.
Apr 29 · 3 min read
Pharma, AI
AI in Pharma Is an Architecture Decision, Not a Procurement One
Most pharma boardrooms ask which AI model to buy. The companies winning are asking which architecture to build. Here is why that matters.
Apr 8 · 3 min read
Questions
What people ask about ai governance.
Want to talk about how this applies to your organization?
30 minute call. No deck. We will figure out if I can help.